Peer-reviewed veterinary case report
Cyclosporin A treatment for intrinsic atopic dermatitis in dogs
By Fujimura, M et al.·Published in Polish journal of veterinary sciences·2016·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Cyclosporin A Treatment in Intrinsic Canine Atopic Dermatitis (Atopic-like Dermatitis): Open Trial Study.
- Species:
- dog
Plain-English summary
A group of dogs with skin allergies was treated with an immunosuppressant called Cyclosporin A to see how well it worked for their itching and skin problems. The dogs were divided into two groups: one with a common type of skin allergy and another with a less common type. The dogs with the less common type showed significant improvement, with most of them experiencing complete relief from their symptoms. However, the dogs with the more common type did not show much change. Overall, Cyclosporin A was effective for dogs with the atopic-like dermatitis but not for those with typical atopic dermatitis.
People also search for: dog skin allergies treatment · Cyclosporin A for dogs · why is my dog itching · atopic dermatitis in dogs · dog skin problems remedies
Abstract
In this study, dogs were separated into two groups and treated with immunosuppressant (Cyclosporin A: CsA). The first group was the canine atopic dermatitis (CAD) group, which is similar to extrinsic atopic dermatitis (AD) in humans (treated with a CsA dose of 2.5-5.5 mg/kg, n=8), and the second group was the canine atopic-like dermatitis (ALD) group, which is similar to intrinsic AD in humans (treated with a CsA dose of 2.5-6.5 mg/kg, n=14). The canine atopic dermatitis extent and severity index (CADESI)-4 was evaluated before treatment (PRE) and after treatment (POST) to assess the effectiveness of CsA for the two groups. In the CAD group, CADESI-4 showed no change (PRE:79±29, POST:77±28) and out of the eight dogs, no dogs showed complete remission, three dogs showed partial remission, and five dogs showed no effect. Whereas in the ALD group, CADESI-4 showed a significant reduction (PRE: 61±42, POST: 32±25, p<0.01) and out of the 14 dogs, 11 dogs showed complete remission, two dogs showed partial remission, and one dog showed no effect. The results indicate that the immunosuppressant showed effectiveness for the dogs diagnosed with ALD. One dog had to be treated for a year and eight months, which was the longest period in the study, this dog presented with hyperplasia of the lymphoidgland and mammary tumor.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27760033/